Heparan Sulfate in Alzheimer's Disease: Aberrant expression and functions in molecular 2 pathways related to amyloid-β metabolism 3
IO McMillan, J Li, L Wang, L Wang - journals.physiology.org
Heparan Sulfate in Alzheimer's Disease: Aberrant expression and functions in molecular
pathways related to amyloid-β metabolism Page 1 1 1 Heparan Sulfate in Alzheimer's Disease …
pathways related to amyloid-β metabolism Page 1 1 1 Heparan Sulfate in Alzheimer's Disease …
BV2 mikroglial hücrelerinde LPS ile indüklenen inflamasyonda oluşan sitokin değişimlerinin tespit edilip, CRP ve kininogen-1'in deiminasyonunun western blot ile …
G Demirel - 2023 - acikerisim.erbakan.edu.tr
Özet Nörodejenerasyon; prevalansı hızla artan ve tedavide güçlükler yaşanan birçok
nörodejeneratif hastalığın ortak özelliğidir. Posttranslasyonel modifikasyonlardan biri olan …
nörodejeneratif hastalığın ortak özelliğidir. Posttranslasyonel modifikasyonlardan biri olan …
Investigating the Role of APOE2 in Alzheimer's Disease Using Human Induced Pluripotent Stem Cell Derived Neurons and Astrocytes
S Raman - 2021 - search.proquest.com
Genome wide association studies (GWAS) have identified polymorphism in the
Apolipoprotein E (APOE) gene to be the most prominent risk factor for Alzheimer's disease …
Apolipoprotein E (APOE) gene to be the most prominent risk factor for Alzheimer's disease …
Cell-Type Specific Expression of Apolipoprotein E by Astrocytes and Microglia: Implications for the Development of Amyloid-β Pathology in Alzheimer Disease
TE Mahan - 2021 - search.proquest.com
Alzheimer disease (AD) is characterized by two main pathological hallmarks, extracellular
amyloid plaques primarily comprised of the amyloid-β (Aβ) peptide, and intracellular …
amyloid plaques primarily comprised of the amyloid-β (Aβ) peptide, and intracellular …
Engineering Human Induced Pluripotent Stem Cells (hiPSCs) to Investigate the Contribution of the APOE Risk Allele to the Onset and Progression of Alzheimer's …
N Brookhouser - 2020 - search.proquest.com
Developing therapies for the treatment of Alzheimer's disease (AD) requires an in-depth
understanding of disease etiology. Although the majority of AD patients are sporadic …
understanding of disease etiology. Although the majority of AD patients are sporadic …
[PDF][PDF] Lipoprotein-mediated brain cholesterol transport: a potential pharmacological target in Alzheimer's Disease
C Marchi - 2020 - repository.unipr.it
STATE OF THE ART: AD is a multifactorial neurodegenerative disease clinically
characterized by a progressive cognitive impairment. Alterations of cholesterol homeostasis …
characterized by a progressive cognitive impairment. Alterations of cholesterol homeostasis …
Therapeutic approaches to ApoE
L Kraft - 2019 - sussex.figshare.com
Apolipoprotein E4 (ApoE4) is the major genetic risk factor in Alzheimer's disease (AD) and
homozygous individuals are at 12-fold greater risk developing the disorder. Three ApoE …
homozygous individuals are at 12-fold greater risk developing the disorder. Three ApoE …
HDL Mimetic Peptides as Potential Therapeutics for Alzheimer's Disease
D Chernick - 2018 - search.proquest.com
Alzheimer's disease (AD) is the leading cause of dementia worldwide, for which there
currently exists no approved disease modifying treatment. A number of large scale human …
currently exists no approved disease modifying treatment. A number of large scale human …
Caractérisation du site de liaison du cholestérol sur l'APP: un modulateur de la sécrétion de peptides amyloïdes
L Hanbouch - 2017 - theses.hal.science
La maladie d'Alzheimer (MA) se caractérise par une perte mnésique progressive. La
quantité de cholestérol est plus élevée dans les cerveaux de patients atteints de la MA. De …
quantité de cholestérol est plus élevée dans les cerveaux de patients atteints de la MA. De …